Scailyte and Visterra Partner to Advance Autoimmune Disease Research

December 17 2024, Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.

The collaboration will leverage Scailyte’s proprietary AI platform, ScaiVision®, and Visterra’s expertise in biologics research to identify and validate novel biomarkers and therapeutic targets. ScaiVision® will analyze complex single-cell data to uncover disease patterns and potential points of intervention.

“We are excited to partner with Visterra to advance our shared goal of developing more effective treatments for autoimmune diseases,” said Peter Nestorov, CEO at Scailyte. “By combining our AI-powered biomarker discovery platform with Visterra’s deep understanding of disease biology, we believe we can accelerate the development of much-needed therapies.”

About Visterra

Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.